CD147 supports paclitaxel resistance via interacting with RanBP1

Gang Nan,Shu-Hua Zhao,Ting Wang,Dong Chao,Ruo-Fei Tian,Wen-Jing Wang,Xin Fu,Peng Lin,Ting Guo,Bin Wang,Xiu-Xuan Sun,Xi Chen,Zhi-Nan Chen,Shi-Jie Wang,Hong-Yong Cui

DOI: https://doi.org/10.1038/s41388-021-02143-3

IF: 8.756

2022-01-01

Oncogene

Abstract:Abstract Though the great success of paclitaxel, the variable response of patients to the drug limits its clinical utility and the precise mechanisms underlying the variable response to paclitaxel remain largely unknown. This study aims to verify the role and the underlying mechanisms of CD147 in paclitaxel resistance. Immunostaining was used to analyze human non-small-cell lung cancer (NSCLC) and ovarian cancer tissues. RNA-sequencing was used to identify downstream effectors. Annexin V-FITC/propidium iodide and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining were used to detect apoptosis. Co-immunoprecipitation (Co-IP), fluorescence resonance energy transfer (FRET) and surface plasmon resonance (SPR) were performed to determine protein interactions. Fluorescence recovery after photobleaching (FRAP) was performed to measure the speed of microtubule turnover. Xenograft tumor model was established to evaluate sensitivity of cancer cells to paclitaxel in vivo. In vitro and in vivo assays showed that silencing CD147 sensitized the cancer cells to paclitaxel treatment. CD147 protected cancer cells from paclitaxel-induced caspase-3 mediated apoptosis regardless of p53 status. Truncation analysis showed that the intracellular domain of CD147 (CD147 ICD ) was indispensable for CD147-regulated sensitivity to paclitaxel. Via screening the interacting proteins of CD147 ICD , Ran binding protein 1 (RanBP1) was identified to interact with CD147 ICD via its C-terminal tail. Furthermore, we showed that RanBP1 mediated CD147-regulated microtubule stability and dynamics as well as response to paclitaxel treatment. These results demonstrated that CD147 regulated paclitaxel response by interacting with the C-terminal tail of RanBP1 and targeting CD147 may be a promising strategy for preventing paclitaxel resistant.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the specific role of CD147 in paclitaxel resistance in non - small - cell lung cancer (NSCLC) and ovarian cancer and its underlying mechanisms. Although paclitaxel has achieved remarkable success in cancer treatment, the differences in patients' responses to this drug limit its clinical application, and the specific mechanisms of these response differences remain unclear. The study analyzed CD147 expression in human non - small - cell lung cancer and ovarian cancer tissues through immunohistochemistry, used RNA sequencing to identify downstream effector factors, and determined protein - protein interactions through various experimental techniques such as co - immunoprecipitation (Co - IP), fluorescence resonance energy transfer (FRET), and surface plasmon resonance (SPR), aiming to verify the role of CD147 in paclitaxel resistance and its mechanism of action.

The study found that CD147 interacts with the C - terminal tail of Ran - binding protein 1 (RanBP1) to regulate microtubule stability and dynamics, thereby affecting the response to paclitaxel. Specifically, the intracellular domain of CD147 (CD147ICD) is crucial for regulating sensitivity to paclitaxel. Silencing CD147 can increase the sensitivity of cancer cells to paclitaxel treatment, while over - expressing CD147 has the opposite effect. In addition, the study also confirmed that RanBP1 mediates the effect of CD147 on the paclitaxel response, and both in vitro cell experiments and in vivo xenograft tumor model experiments support this conclusion.

These results indicate that CD147 is involved in regulating the response to paclitaxel through its interaction with RanBP1, and targeting CD147 may become a promising strategy for preventing paclitaxel resistance.